Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Gastro-enteropancreatic neuroendocrine tumor × pasireotide × Clear all

Phase

Phase 3 2 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Prostatic Neoplasms 1 Pituitary Neoplasms 1 Pituitary ACTH Hypersecretion 1 Pancreatic Neoplasms 1 Pancreatic Fistula 1 Neuroendocrine Tumors 1 Neoplasms 1 Melanoma 1 Hypoglycemia 1 Gastro-enteropancreatic neuroendocrine tumor 1 Dumping Syndrome 1 Acromegaly 1

Interventions

pasireotide 1 lanreotide 1 arginyllysine 1 Somatostatin 1 Octreotide 1 Diazoxide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡